Regulatory actions provided the impetus to big moves for these five biotech stocks.
News & Analysis: Navidea Biopharmaceuticals
Navidea shares head the wrong way after a thumbs-up from the FDA.
Navidea shares soar after announcing an encouraging post-hoc analysis of its phase 3 study involving Lymphoseek. Find out if shares can head even higher.
Navidea shares ascend after reporting its fourth-quarter earnings results. Here's the one thing investors should really be watching.
Navidea shares soar after receiving the fast track designation for its lead product. Is now the time to sell or are the good times just getting started?
The implementation of Obamacare could lead to a surge in preventative care diagnostic tests, which would suit these three health care stocks very well.
A once "golden" stock, a promising medical diagnostics company, and a sneaky play in the oil and gas sector top this week's must-adds to your Watchlist.
Many of us implicitly trust our physicians to be right, but that isn't always the case. Here are the five most commonly misdiagnosed diseases and what might be done to help prevent misdiagnoses in the future.
Is it crazy to hope for 100% gains in 12 months? Not in the biotech sector. Here are 3 stocks that could double by next summer with a few lucky breaks.
Jolie's personal experiences brings the dangers of breast cancer into new light and also gives hope to current and future breast cancer sufferers thanks to improving therapies and diagnostic tests.